Terremoto Raises $108M to Make an 'Earthquake' in Small Molecule Space

Terremoto raised $108M in Series C funding12

The funding will support clinical trial development of drugs targeting AKT2

The company is focusing on small molecule drug development1

The funding round has been reported as recent news across multiple biotech publications12

Sources:

1. https://www.nie-podam.pl/wiadomosci/112258103

2. https://www.brutalist.bio